<div id="readability-page-1"><p>Woodstock Corp raised its stake in shares of  Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 107.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 16,610 shares of the biopharmaceutical company's stock after buying an additional 8,589 shares during the period. Woodstock Corp's holdings in Regeneron Pharmaceuticals were worth $9,339,000 at the end of the most recent quarter.</p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. Assenagon Asset Management S.A. raised its stake in shares of  Regeneron Pharmaceuticals by 12.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 477,810 shares of the biopharmaceutical company's stock valued at $268,658,000 after acquiring an additional 54,485 shares in the last quarter.  Traphagen Investment Advisors LLC boosted its position in  Regeneron Pharmaceuticals by 2.7% during the third quarter. Traphagen Investment Advisors LLC now owns 911 shares of the biopharmaceutical company's stock worth $512,000 after purchasing an additional 24 shares during the period.  Sicart Associates LLC acquired a new position in  Regeneron Pharmaceuticals during the third quarter valued at approximately $3,925,000.  Union Bancaire Privee UBP SA raised its position in shares of  Regeneron Pharmaceuticals by 10,440.0% in the third quarter. Union Bancaire Privee UBP SA now owns 517 shares of the biopharmaceutical company's stock valued at $291,000 after purchasing an additional 522 shares during the period.  Finally, Moody National Bank Trust Division lifted its stake in shares of  Regeneron Pharmaceuticals by 19.2% in the third quarter. Moody National Bank Trust Division now owns 1,786 shares of the biopharmaceutical company's stock worth $1,004,000 after buying an additional 288 shares during the last quarter. Institutional investors and hedge funds own  83.31% of the company's stock. </p><h2>Insider Buying and Selling at Regeneron Pharmaceuticals</h2><p>In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company's stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by corporate insiders. </p><h2>Analysts Set New Price Targets</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>A number of research analysts recently issued reports on REGN shares. Canaccord Genuity Group raised their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, December 4th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Monday, November 17th. Truist Financial assumed coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a &#34;buy&#34; rating and a $798.00 price objective on the stock. Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, Raymond James Financial raised Regeneron Pharmaceuticals to a &#34;moderate buy&#34; rating in a report on Tuesday, September 2nd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned  a Buy rating, eight have given a Hold rating and one  has assigned  a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $779.45.</p><p><b>View Our Latest Stock Report on Regeneron Pharmaceuticals</b></p><h2>Regeneron Pharmaceuticals Stock Down 0.8%</h2><ul><li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li></ul><p>REGN stock opened at $746.36 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $790.98. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The company has a market cap of $78.44 billion, a PE ratio of 17.87, a price-to-earnings-growth ratio of 2.15 and a beta of 0.37. The business's 50-day simple moving average is $671.04 and its 200 day simple moving average is $595.57. </p><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts' consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter last year, the company earned $12.46 EPS. The company's quarterly revenue was up .9% on a year-over-year basis.  On average, research analysts anticipate that  Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year. </p><h2>Regeneron Pharmaceuticals Dividend Announcement</h2><p>The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 8.43%. </p><h2>Regeneron Pharmaceuticals Profile</h2> (Free Report)<p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Regeneron Pharmaceuticals</li><li>How to Find Undervalued Stocks</li><li>3 Tech Stocks Down Over 60%—Which One Is Worth Buying?</li><li>What is the Nasdaq? Complete Overview with History</li><li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li><li>What is a Death Cross in Stocks?</li><li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li></ul><p><strong>Want to see what other hedge funds are holding REGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

REGN

<p>Woodstock Corp increased its stake in Regeneron Pharmaceuticals by 107.1% in Q3, owning 16,610 shares worth $9,339,000. Other investors also adjusted their positions in REGN. Insider sales included Director Christine A. Poon and VP Jason Pitofsky. Analysts issued new price targets, with a consensus rating of "Moderate Buy" and an average price target of $779.45. REGN stock opened at $746.36, with a 12-month low of $476.49 and high of $790.98.</p>

Woodstock Corp Acquires 8,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN